By Marleen Kaesebier BASEL, Switzerland, May 5 (Reuters) - Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain and pharmaceutical companies sought out collaborative deals with biotech firms, a report on the sector showed on Tuesday. While total funding for the sector increased 2.1% to 2.6 billion Swiss francs ($3.32 billion), the amount for privately funded companie…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.